BIO President and CEO Jim Greenwood penned an op-ed for the September issue of BioPharm International on the importance of technology transfer from academia to industry, as encouraged by the Bayh-Dole Act of 1980.
The Bayh-Dole Act, which permits and encourages industry to partner with research universities to turn federally-funded basic research into new and valuable products, is a critical factor in driving America’s innovation economy. Because of this legislation, the U.S. leads the world in commercializing university-based research to create new companies and good, high-paying jobs throughout the country.
To read the full, original article click on this link: Tech Transfer: Promoting Public-Private Collaborations for Innovation | BIOtechNow
